Survival after progression or relapse in intention-to-treat population and according to thalidomide or bortezomib salvage-treatment. Overall survival from relapse in intention-to-treat population (A), according to thalidomide/bortezomib salvage treatment for melphalan and prednisone patients (B) and for melphalan, prednisone, thalidomide (C). MPT indicates melphalan, prednisone, and thalidomide; MP, melphalan and prednisone; HR, hazard ratio; CI, confidence interval; Thal, thalidomide; and Bor, bortezomib.